Skip to main content
. Author manuscript; available in PMC: 2020 Mar 15.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2018 Nov 14;103(4):851–860. doi: 10.1016/j.ijrobp.2018.11.013

Fig. 2.

Fig. 2.

Proportion of patients with potentially clinically significant elevation in biomarker levels from pre-RT to completion of RT in breast cancer (A) and lung cancer/mediastinla lymphoma (B). The height of the bars represents the proportion of patients who developed potentially clinically significant elevations in biomarkers from pre-RT to the completion of RT (i.e., >30% elevation or increase to >14 ng/L for hs-cTnT, and >30% elevation for the other biomarkers). Abbreviations: GDF-15 = growth differention factor 15; hs-cTnT = high sensitivity cardiac troponin T; NT-proBNP = Nterminal B-type natriuretic peptide; PIGF = placental growth factor; RT = radiation therapy.